<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412017000300141</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Mioinositol en combinación con D-chiro-inositol: resultados preliminares en el tratamiento de primera línea de pacientes con síndrome de ovario poliquístico]]></article-title>
<article-title xml:lang="en"><![CDATA[Myoinositol plus D-chiro-inositol: Preliminary results as first line management in PCOS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carmona-Ruiz]]></surname>
<given-names><![CDATA[IO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saucedo-de-la-Llata]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moraga-Sánchez]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romeu-Sarrió]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Clínica Imar  ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Clínica Imar  ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Clínica Imar  ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Clínica Imar  ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2017</year>
</pub-date>
<volume>85</volume>
<numero>3</numero>
<fpage>141</fpage>
<lpage>151</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412017000300141&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412017000300141&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412017000300141&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Evaluar el efecto de la combinación de mioinositol y D-chiro-inositol en el perfil metabólico y endocrino de mujeres con síndrome de ovario poliquístico.  MATERIALES Y MÉTODOS: Estudio experimental, prospectivo y longitudinal efectuado en pacientes con diagnóstico de síndrome de ovario poliquístico (criterios de Rotterdam) sin tratamiento o intervención previa. Diariamente se administraron, por vía oral, 2000 mg de mioinositol y 400 mg de D-chiro-inositol, durante 90 días. Se evalúan y comparan el perfil clínico y metabólico de cada paciente antes y después de la intervención.  RESULTADOS: Se estudiaron 61 pacientes con síndrome de ovario poliquístico, con una diferencia estadísticamente significativa en los valores de la escala Ferriman-Gallwey (6.06 ± 2.0 y 5.57 ± 1.1; p = 0.003 pre y postratamiento, respectivamente); volumen ovárico izquierdo (7.76 ± 3.2 y 7.18 ± 2.3; p = 0.005, pre y postratamiento, respectivamente). La cuenta de folículos antrales del ovario izquierdo fue de 10.65 ± 6.4 y 10.20 ± 5.7; p=0.029 pre y postratamiento, respectivamente. La cuenta de folículos antrales del ovario derecho fue: 12.11 ± 6.5 y 11.75 ± 6.1; p=0.048 pre y postratamiento, respectivamente. Hubo mejoría en los valores del HOMA (1.85 ± 1.0 y 1.67 ± 0.7; p=0.015 pre y postratamiento, respectivamente. En la proporción LH-FSH: 1.13 ± 0.8 y 0.99 ± 0.6; p=0.018 pre y postratamiento, respectivamente.  CONCLUSIÓN: Los resultados del estudio muestran un efecto positivo de la administración combinada de mioinositol y D-chiro-inositol en el perfil clínico y metabólico de pacientes con síndrome de ovario poliquístico. La mejora en las concentraciones séricas de andrógenos, de la proporción LH-FSH y la regularización de los ciclos menstruales puede contribuir al aumento de la fertilidad en pacientes con síndrome de ovario poliquístico y factor ovárico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: To assess the effect of a combined therapy with myoino-sitol (MI) and D-chiro-inositol (DCI) in Polycystic Ovary Syndrome (PCOS) patients.  MATERIALS AND METHODS: An experimental, prospective, longitudinal study. It includes patients with PCOS diagnostic (by Rotterdam criteria) that have not received any form of therapy or management for the syndrome. All patients received an oral daily administration of MI and DCI for 90 days. Clinic and metabolic profiles are assessed pre and postreatment.  RESULTS: Sixty-one patients are included and we observed an improvement in Ferriman-Gallwey scale (6.06 ± 2.0 y 5.57 ± 1.1; p=0.003, pre-and postreatment, respectively); left ovary volume (7.76 ± 3.2 y 7.18 ± 2.3; p=0.005, pre and postreatment, respectively). Left ovary antral follicle count (10.65 ± 6.4 y 10.20 ± 5.7; p=0.029, pre and postreatment, respectively) and right ovary antral follicle count (12.11 ± 6.5 y 11.75 ± 6.1, p=0.048, pre and postreatment, respectively). There is also an improvement in HOMA (1.85 ± 1.0 y 1.67 ± 0.7, p=0.015, pre and postreatment, respectively) and LH/FSH ratio (1.13 ± 0.8 y 0.99 ± 0.6, p=0.018 pre and post treatment, respectively).  CONCLUSION: We observed a positive effect with the combined administration of MI and DCI in clinic and metabolic profile of PCOS patients. Improvement in androgen profile, LH/FSH ratio and restoring menstrual cycles, may have a positive effect over the infertility caused by an anovulatory factor.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[síndrome de ovario poliquístico]]></kwd>
<kwd lng="es"><![CDATA[inositol]]></kwd>
<kwd lng="es"><![CDATA[síndrome de ovario poliquístico e inositol]]></kwd>
<kwd lng="es"><![CDATA[tratamiento del síndrome de ovario poliquístico]]></kwd>
<kwd lng="en"><![CDATA[Polycystic ovary syndrome]]></kwd>
<kwd lng="en"><![CDATA[PCOS]]></kwd>
<kwd lng="en"><![CDATA[Inositol]]></kwd>
<kwd lng="en"><![CDATA[PCOS treatment]]></kwd>
<kwd lng="en"><![CDATA[PCOS inositol treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azziz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hoq]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Badamgarav]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Endocrinology and Metabolism]]></source>
<year>2005</year>
<volume>90</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>4650-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Endocrinology and Metabolism]]></source>
<year>1999</year>
<volume>84</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1897-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rosato]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Janni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Endocrinology and Metabolism]]></source>
<year>2006</year>
<volume>91</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The metabolic syndrome in polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Essah]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Endocrinological Investigation]]></source>
<year>2006</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>270-80</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Consensus on women's health aspects of polycystic ovary syndrome (PCOS)]]></article-title>
<collab>Amsterdam EA-SrPCWG</collab>
<source><![CDATA[Human Reproduction]]></source>
<year>2012</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-24</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knochenhauer]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Key]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kahsar-Miller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Waggoner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Boots]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Azziz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Endocrinology and Metabolism]]></source>
<year>1998</year>
<volume>83</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3078-82</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asuncion]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[San Millan]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Sancho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Avila]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar-Morreale]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Endocrinology and Metabolism]]></source>
<year>2000</year>
<volume>85</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2434-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The prevalence and features of the polycystic ovary syndrome in an unselected population]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azziz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Woods]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Reyna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Key]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knochenhauer]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Yildiz]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
</person-group>
<source><![CDATA[The Journal of Clinical Endocrinology and Metabolism]]></source>
<year>2004</year>
<volume>89</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2745-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lauritsen]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Bentzen]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Pinborg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Loft]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Forman]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Thuesen]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Reproduction]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polycystic ovaries and associated clinical and biochemical features in young women]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michelmore]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Balen]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Dunger]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Vessey]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Endocrinology]]></source>
<year>1999</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>779-86</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[[Polycystic ovary syndrome: is there a rise in the prevalence?]]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmona-Ruiz]]></surname>
<given-names><![CDATA[IO]]></given-names>
</name>
<name>
<surname><![CDATA[Saucedo-de la Llata]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moraga-Sanchez]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Romeu-Sarro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2015</year>
<volume>83</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>750-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Seminars in Reproductive Endocrinology]]></source>
<year>1997</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin sensitizers for polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Iuorno]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Obstetrics and Gynecology]]></source>
<year>2003</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>325-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genazzani]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Battaglia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Malavasi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Strucchi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tortolani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gamba]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2004</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>114-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciampelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fulghesu]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cucinelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pavone]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ronsisvalle]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Guido]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Metabolism: Clinical and Experimental]]></source>
<year>1999</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>167-72</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dante]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Facchinetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecological endocrinology: the official Journal of the International Society of Gynecological Endocrinology]]></source>
<year>2012</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>509-15</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin resistance in women with polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunaif]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2006</year>
<volume>86</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>S13-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasquali]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pelusi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ragazzini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hasanaj]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gambineri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of the Pancreas]]></source>
<year>2002</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genazzani]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Lanzoni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ricchieri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baraldi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Casarosa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jasonni]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecological Endocrinology]]></source>
<year>2007</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>146-52</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin-sensitizing agents in polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasquali]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gambineri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[European journal of endocrinology / European Federation of Endocrine Societies]]></source>
<year>2006</year>
<volume>154</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>763-75</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Fonteles]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Houston]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Larner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrinology]]></source>
<year>1993</year>
<volume>132</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>652-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecular Human Reproduction]]></source>
<year>2007</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>527-35</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[International Journal of Experimental Diabetes Research]]></source>
<year>2002</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-60</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physiological role and clinical utility of inositols in polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bevilacqua]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bizzarri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Best Practice &amp; Research Clinical Obstetrics and Gynaecology]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome]]></article-title>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2004</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-25</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)]]></article-title>
<source><![CDATA[Human Reproduction]]></source>
<year>2004</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dewailly]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gronier]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Poncelet]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Robin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Leroy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pigny]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Reproduction]]></source>
<year>2011</year>
<volume>26</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3123-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Different perspectives of patients and health care professionals on the potential benefits and risks of blastocyst culture and multiple embryo transfer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartshorne]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Lilford]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Reproduction]]></source>
<year>2002</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1023-30</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nandi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Poretsky]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrinology and metabolism. Clinics of North America]]></source>
<year>2014</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>123-47</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polycystic ovary syndrome: etiology, pathogenesis and diagnosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodarzi]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Dumesic]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Chazenbalk]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Azziz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2011</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>219-31</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Semple]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2016</year>
<volume>174</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>R209-23</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dewailly]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Legro]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Hickey]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>370</volume>
<numero>9588</numero>
<issue>9588</issue>
<page-range>685-97</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunaif]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocr Rev]]></source>
<year>1997</year>
<volume>18</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>774-800</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular mechanisms of insulin resistance in polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diamanti-Kandarakis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Papavassiliou]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<source><![CDATA[Trends in Molecular Medicine]]></source>
<year>2006</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>324-32</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolodziejczyk]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Duleba]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spaczynski]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Pawelczyk]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2000</year>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1149-54</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trolle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Flyvbjerg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kesmodel]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lauszus]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Reproduction]]></source>
<year>2007</year>
<volume>22</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2967-73</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palomba]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Falbo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Di Cello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cappiello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tolino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zullo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2011</year>
<volume>96</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1128-33</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rosiglitazone, myocardial ischemic risk, and recent regulatory actions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourg]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2012</year>
<volume>46</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>282-9</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ACOG Practice Bulletin No. 108: Polycystic ovary syndrome]]></article-title>
<collab>Bulletins--Gynecology ACoP</collab>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2009</year>
<volume>114</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>936-49</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nestler]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Jakubowicz]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reamer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gunn]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Allan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[The New England Journal of Medicine]]></source>
<year>1999</year>
<volume>340</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1314-20</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iuorno]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jakubowicz]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gunn]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Allan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists]]></source>
<year>2002</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>417-23</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheang]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Essah]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Ostlund Jr]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Apridonize]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Metabolism: Clinical and Experimental]]></source>
<year>2008</year>
<volume>57</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1390-7</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Tam]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Assisted Reproduction and Genetics]]></source>
<year>1992</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>524-30</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Briton-Jones]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Haines]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Reproduction]]></source>
<year>2002</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1591-6</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papaleo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fusi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brigante]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecological Endocrinology]]></source>
<year>2007</year>
<volume>23</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>700-3</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Papaleo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Di Renzo]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2007</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>347-54</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costantino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Minozzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Minozzi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Guaraldi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[European Review for Medical and Pharmacological Sciences]]></source>
<year>2009</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-10</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genazzani]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Lanzoni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ricchieri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jasonni]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecological Endocrinology]]></source>
<year>2008</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>139-44</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papaleo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fusi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Occhi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2009</year>
<volume>91</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1750-4</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myoinositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Raffone]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Roseff]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[European Review for Medical and Pharmacological Sciences]]></source>
<year>2011</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>452-7</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harwood]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vuguin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[DiMartino-Nardi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Hormone Research]]></source>
<year>2007</year>
<volume>68</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>209-17</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polycystic ovary syndrome: etiology and pathogenesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matalliotakis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kourtis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Koukoura]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Panidis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Gynecology and Obstetrics]]></source>
<year>2006</year>
<volume>274</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>187-97</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rice]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Christoforidis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gadd]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolaou]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Seyani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Donaldson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Human Reproduction]]></source>
<year>2005</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>373-81</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The D-chiro-inositol paradox in the ovary]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Roseff]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Fertility and Sterility]]></source>
<year>2011</year>
<volume>95</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2515-6</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chattopadhayay]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ganesh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Samanta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jana]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Chakravarty]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Chaudhury]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecologic and Obstetric Investigation]]></source>
<year>2010</year>
<volume>69</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>197-202</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Does ovary need D-chiro-inositol?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isabella]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Raffone]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Ovarian Research]]></source>
<year>2012</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galletta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grasso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vaiarelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roseff]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[European Review for Medical and Pharmacological Sciences]]></source>
<year>2011</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1212-4</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Grazia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Manna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert opinion on drug delivery]]></source>
<year>2012</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>267-71</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nordio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Proietti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[European Review for Medical and Pharmacological Sciences]]></source>
<year>2012</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>575-81</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lagana]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Barbaro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pizzo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Archives of Gynecology and Obstetrics]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[La Marca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grisendi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dondi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sighinolfi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cianci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Gynecological Endocrinology]]></source>
<year>2014</year>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Facchinetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bizzarri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Benvenga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[D'Anna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lanzone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soulage]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[European journal of obstetrics, gynecology, and reproductive biology]]></source>
<year>2015</year>
<volume>195</volume>
<page-range>72-6</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broekmans]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knauff]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Valkenburg]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Laven]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Eijkemans]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fauser]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<source><![CDATA[BJOG : an international journal of obstetrics and gynaecology]]></source>
<year>2006</year>
<volume>113</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1210-7</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The polycystic ovary syndrome: a position statement from the European Society of Endocrinology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conway]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dewailly]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Diamanti-Kandarakis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar-Morreale]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Franks]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gambineri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Endocrinol]]></source>
<year>2014</year>
<volume>171</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>P1-29</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
